Innovent Reveals Key Goal Achieved in Phase 3 Study (RESTORE-1) of IBI311 (IGF-1R-Targeting Agent) for Thyroid Eye Condition, Intends to File for Approval with NMPA.

Bayer commences a second-stage trial using a novel anti-alpha2 antiplasmin agent in individuals affected by deep venous clots.

EU Regulatory Body Sanctions Pfizer's VELSIPITY® Use in Individuals with Moderate to Severe Ulcerative Colitis Cases.

Genentech announced that the US FDA has approved Xolair (omalizumab) for reducing allergic reactions.

US authorities greenlight a combined treatment of TAGRISSO® (osimertinib) and chemotherapy for individuals battling advanced lung cancer with EGFR mutations.

U.S. Authorities Approve Review for Deruxtecan-Datopotamab Treatment Submission for Earlier Managed Advanced Non-Squamous NSCLC Cases.

Almirall gains rights to develop Novo Nordisk’s anti-IL-21 antibody for dermatologic applications as a pioneering treatment.

Citius Pharma re-submits its LYMPHIR™ BLA, comprising Denileukin Diftitox, aiming to treat relapsed/refractory Cutaneous T-Cell Lymphoma in adults.

Kurome Therapeutics has received authorization from the FDA to conduct clinical trials for KME-0584, aimed at addressing Acute Myeloid Leukemia (AML) and advanced-stage Myelodysplastic Syndromes (MDS).

Acousia Therapeutics disclosed that it has initiated participant enrollment for its second stage PROHEAR trial.

Curadev proudly launches CRD3874, an innovative allosteric small molecule that uniquely activates the STING pathway without targeting the cGAMP site.

Repare Therapeutics Inc. announced the first patient has been treated in their LIONS Phase 1 trial, focusing on RP-1664 – a leading oral inhibitor targeting polo-like kinase 4, intended for solo therapy.